Membranous Nephropathy Treatment Market Snapshot (2023 to 2033)
The global membranous nephropathy treatment market is expected to be valued at US$ 181.2 million in 2022. By 2023 and 2033, this market is expected to produce values worth US$ 190 million and US$ 332 million, respectively, growing at a CAGR of 5.65%.
Data Points
Key Statistics
Expected Market Value in 2023
US$ 190 million
Expected Market Value in 2033
US$ 332 million
Growth Rate (2023 to 2033)
CAGR of 5.65%
The market for membranous nephropathy is primarily driven by increased rates of renal disease, an aging population that results in an increase in patients, hepatitis infections, as well as a rise in the number of young people who lead sedentary lifestyles. The market will likely be driven by government financing, an increase in the need for innovative therapies, and market participants that are supplying cutting-edge technologies.
According to figures from the United Nations, there were greater than 962 million persons worldwide who were 60 years of age or older in 2017. By 2050, there may be 425 million older adults worldwide, according to the UN. In addition, the World Health Organization estimates that 71 million individuals globally have hepatitis C. The market for treatments for membranous nephropathy is projected to expand due to an older population and an increase in hepatitis incidence. The requirement for greater knowledge of the treatment is one factor preventing the market's expansion.
The membranous nephropathy treatment market is projected to increase due to the rising elderly population throughout the world and the target demographic thought to have the condition. The membranous nephropathy treatment market for kidney transplantation may be hampered by complications related to kidney transplantation and the likelihood of membranous nephropathy recurrence in patients. However, the market may see a rise due to technical improvements and an expansion of treatment choices brought on by rising healthcare spending.
Correct evaluation and therapy result from a shortage of experienced specialists, which makes the procedure easier and more convenient. Patients may have difficulties if their condition is mistreated, which presents a difficult obstacle to the market's expansion for treatments for membranous nephropathy. As a result, the market's CAGR for membranous nephropathy treatment has been rising recently.
The North American market for the treatment of membranous nephropathy reached over US$ 121 million in 2022 and is anticipated to increase at a substantial CAGR throughout the research period. The market is projected to be driven by the rising elderly population and the rising prevalence of hepatitis in the general population. Moreover, the expansion of the North American membranous nephropathy treatment market is projected to be aided by increased healthcare spending, a need for technologically sophisticated goods and treatments, and expanding government backing.
Market participants are engaging in a range of strategic activities to broaden their reach internationally along with important market developments including the launch of new goods, mergers and acquisitions, contractual agreements, higher investments, and cooperation with other organisations. Businesses in the membranous nephropathy sector must provide products that are affordable if they want to grow and thrive in a market that is becoming more and more competitive. Not only are they developing treatments that suit this market, but for other diseases and illnesses as well, which helps in boosting the global presence of the key players.
Abbvie announced in March 2022 that it will purchase Belgium-based Syndesi Therapeutics, together with its main drug SDI-118 and portfolio of new modulators of synaptophysin 2A, for up to $1 million. AbbVie announced in October 2022 that they will pay $225 million to purchase the UK-based biotechnology business DJS Antibodies, gaining access to an investigational treatment for severe lung illness and advancing the technology for specific antibody therapies.
Allergan Plc is a US-Irish licensed pharmaceutical corporation that buys, develops, produces, and distributes branded medications and medical equipment for the gastrointestinal, eye care, and central nervous system. It is a firm that makes Botox. AbbVie finalized the acquisition of Allergan on May 8, 2020. From 2023 to 2033, new opportunities in the worldwide market for membranous nephropathy therapy are predicted to arise as a result of these actions by the leading players.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Membranous Nephropathy Treatment Market: Drivers and Restraints
The rise in kidney disorders worldwide and vulnerable aging population is expected to be the leading factors to drive the growth of the membranous nephropathy treatment market. Additionally, ongoing research activities and favourable regulatory scenario related to membranous nephropathy are also expected to boost the membranous nephropathy market during the forecast period.
However, the growth of global membranous nephropathy treatment market may be hampered by discontinuation of the drugs coupled with preference over other therapies.
Membranous Nephropathy is a kidney disease that and can cause protein in the urine and affects the filter of the kidney, and may also decrease the functioning of the kidney function and can cause swelling.
The global membranous nephropathy treatment market is expected to grow at a substantial rate due to the increasing no. of kidney disorders and vulnerable geriatric population worldwide. The membranous nephropathy treatment market is divided on the basis of type, drug class and distribution channel.
The impact of COVID-19 on membranous nephropathy treatment market has started to be felt. The breakout of this disease led to lockdowns across globe which has slowed down the growth of many markets. Membranous nephropathy treatment market is no different. However, the market is expected to catch up and grow rapidly in the forecast years.
Membranous Nephropathy Treatment Market: Overview
Membranous nephropathy treatment market is expected to experience steady growth during the forecast period due to rise in kidney disorders around the globe. Based on treatment type, the market is segmented into primary and secondary. Primary membranous nephropathy is expected to be the higher contributor of revenue is this segment as it is more common as compared to secondary membranous nephropathy.
Based on drug class, the market is segmented intochlorambucil, cyclic peptides, tacrolimus, mycophenolatemofeti,alkylating agents,cyclophosphamide l and others. Alkylating agents and cyclophosphamide are expected to contribute highest revenue in this segment due to it’s effectiveness in treating the membranous nephropathy. Based on distribution channel, market is segmented into retail pharmacy, hospital pharmacy and online pharmacy.
Geographically, themembranous nephropathy treatment marketis segmented into sevenregions viz.North America, South Asia, East Asia, Europe,Latin America, OceaniaandMiddle East and Africa.
The North America is expected to dominate the global membranous treatment market due to increasing no. of hepatitis affected population, along with risinggeriatric population. Moreover, growing healthcare expenditure and rising demand for technologically advanced treatment is expected to boost the market in this region.
Europe is expected to have the second largest market for global membranous nephropathy treatment market as a result of factors like availability of newer and advanced treatment facilities, rising skilled medical professionals and growing need for a better healthcare scenario.
East Asia is expected to observe a substantial growth in the membranous nephropathy treatment market. On the other hand, South Asia is anticipated to experience fastest growth in the membranous nephropathy treatment market due to increasing prevalence of chronic diseases and infections.
Additionally, the rising geriatric and patient population in countries like India and China is expected to be the major drivers in this region. Rising awareness regarding health and availability of new treatment methods is also expected to boost the growth of the market in South Asia.
In the Middle East and Africa the market growth is expected to be limited due to lack of awareness, limited access and availability of treatment facilities,slow economic growth and underdeveloped infrastructure.
Some of the players identified in the membranous nephropathy treatment marketinclude:
Abbie. Inc.
Astrazeneca Plc.
F. Hoffman- La Roche Ltd.
Fibrogen
Allergan Plc.
Amgen Inc
Pfizer Inc.
Novartis. AG.
Apotex Inc.
Teva Pharma Industries Ltd.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology Matrix
Value Chain
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Regional analysis of the membranous nephropathy treatment market report includes
